{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:01:42Z","timestamp":1784613702886,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13878-3","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T17:44:11Z","timestamp":1784396651000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of IL-10 (rs1800896) and TLR3 (rs1879026) polymorphism with progression of hcv-related liver disease and hepatocellular carcinoma in Egyptian patients"],"prefix":"10.1186","volume":"26","author":[{"given":"Ashaimaa A.","family":"Eid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza. H.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad M.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7608-850X","authenticated-orcid":false,"given":"Khaled M.","family":"Aboshanab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"13878_CR1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3390\/gastroent15030049","volume":"15","author":"S Topi","year":"2024","unstructured":"Topi S, Gaxhja E, Charitos IA, Colella M, Santacroce L, Hepatitis C. Virus: History and Current Knowledge. Gastroenterol Insights. 2024;15:676\u2013707. https:\/\/doi.org\/10.3390\/gastroent15030049.","journal-title":"Gastroenterol Insights"},{"key":"13878_CR2","doi-asserted-by":"publisher","unstructured":"Boukaira S, Madihi S, Bouafi H, Rchiad Z, Belkadi B, Benani A. Hepatitis C in North Africa: A Comprehensive Review of Epidemiology, Genotypic Diversity, and Hepatocellular Carcinoma. Adv Virol. 2025;2025. https:\/\/doi.org\/10.1155\/av\/9927410","DOI":"10.1155\/av\/9927410"},{"key":"13878_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/437971","volume":"2014","author":"AS Ibrahim","year":"2014","unstructured":"Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program. J Cancer Epidemiol. 2014;2014:1\u201318. https:\/\/doi.org\/10.1155\/2014\/437971.","journal-title":"J Cancer Epidemiol"},{"key":"13878_CR4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.4254\/wjh.v10.i9.549","volume":"10","author":"II Raad","year":"2018","unstructured":"Raad II, Chaftari A-M, Torres HA, Fahmy E, Narouz LI, Bartek J, et al. Challenge of hepatitis C in Egypt and hepatitis B in Mauritania. World J Hepatol. 2018;10:549\u201357. https:\/\/doi.org\/10.4254\/wjh.v10.i9.549.","journal-title":"World J Hepatol"},{"key":"13878_CR5","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1056\/NEJMsr1912628","volume":"382","author":"I Waked","year":"2020","unstructured":"Waked I, Esmat G, Elsharkawy A, El-Serafy M, Abdel-Razek W, Ghalab R, et al. Screening and Treatment Program to Eliminate Hepatitis C in Egypt. N Engl J Med. 2020;382:1166\u201374. https:\/\/doi.org\/10.1056\/NEJMsr1912628.","journal-title":"N Engl J Med"},{"key":"13878_CR6","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1172\/JCI39133","volume":"119","author":"B Rehermann","year":"2009","unstructured":"Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009;119:1745\u201354. https:\/\/doi.org\/10.1172\/JCI39133.","journal-title":"J Clin Invest"},{"key":"13878_CR7","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1189\/jlb.0506297","volume":"80","author":"A Budhu","year":"2006","unstructured":"Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol. 2006;80:1197\u2013213. https:\/\/doi.org\/10.1189\/jlb.0506297.","journal-title":"J Leukoc Biol"},{"key":"13878_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nri2735","volume":"10","author":"WE Paul","year":"2010","unstructured":"Paul WE, Zhu J. How are TH2-type immune responses initiated and amplified? Nat Rev Immunol. 2010;10:225\u201335. https:\/\/doi.org\/10.1038\/nri2735.","journal-title":"Nat Rev Immunol"},{"key":"13878_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2370.1997.tb00001.x","volume":"24","author":"DM Turner","year":"1997","unstructured":"Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV, POLYMORPHISM IN THE INTERLEUKIN-10 GENE PROMOTER. Eur J Immunogenet. 1997;24:1\u20138. https:\/\/doi.org\/10.1111\/j.1365-2370.1997.tb00001.x.","journal-title":"Eur J Immunogenet"},{"key":"13878_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/cei.13514","volume":"203","author":"SF Abdelwahab","year":"2020","unstructured":"Abdelwahab SF, Hamdy S, Osman AM, Zakaria ZA, Galal I, Sobhy M, et al. Association of the polymorphism of the Toll-like receptor (TLR)-3 and TLR-9 genes with hepatitis C virus-specific cell-mediated immunity outcomes among Egyptian health-care workers. Clin Exp Immunol. 2020;203:3\u201312. https:\/\/doi.org\/10.1111\/cei.13514.","journal-title":"Clin Exp Immunol"},{"key":"13878_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/357062","volume":"2014","author":"AA Al-Qahtani","year":"2014","unstructured":"Al-Qahtani AA, Al-Anazi MR, Al-Zoghaibi F, Abdo AA, Sanai FM, Khan MQ, et al. The Association of Toll-Like Receptor 4 Polymorphism with Hepatitis C Virus Infection in Saudi Arabian Patients. Biomed Res Int. 2014;2014:1\u20139. https:\/\/doi.org\/10.1155\/2014\/357062.","journal-title":"Biomed Res Int"},{"key":"13878_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/1590653","volume":"2017","author":"MR Al-Anazi","year":"2017","unstructured":"Al-Anazi MR, Matou-Nasri S, Abdo AA, Sanai FM, Alkahtani S, Alarifi S, et al. Association of Toll-Like Receptor 3 Single-Nucleotide Polymorphisms and Hepatitis C Virus Infection. J Immunol Res. 2017;2017:1\u201311. https:\/\/doi.org\/10.1155\/2017\/1590653.","journal-title":"J Immunol Res"},{"key":"13878_CR13","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jhep.2009.04.027","volume":"51","author":"Y Li","year":"2009","unstructured":"Li Y, Chang M, Abar O, Garcia V, Rowland C, Catanese J, et al. Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J Hepatol. 2009;51:750\u20137. https:\/\/doi.org\/10.1016\/j.jhep.2009.04.027.","journal-title":"J Hepatol"},{"key":"13878_CR14","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.31557\/APJCP.2023.24.11.3925","volume":"24","author":"G Nurlanova","year":"2023","unstructured":"Nurlanova G, Zhumagaliyeva G, Iskakova A, Astrakhanov A, Kurmangazin M. TLR3 Gene Polymorphism in HCV Infection in the Kazakh Population of Western Kazakhstan. Asian Pac J Cancer Prev. 2023;24:3925\u201330. https:\/\/doi.org\/10.31557\/APJCP.2023.24.11.3925.","journal-title":"Asian Pac J Cancer Prev"},{"key":"13878_CR15","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1007\/s00705-015-2493-0","volume":"160","author":"NAH Sadik","year":"2015","unstructured":"Sadik NAH, Shaker OG, Ghanem HZ, Hassan HA, Abdel-Hamid A-HZ. Single-nucleotide polymorphism of Toll-like receptor 4 and interleukin-10 in response to interferon-based therapy in Egyptian chronic hepatitis C patients. Arch Virol. 2015;160:2181\u201395. https:\/\/doi.org\/10.1007\/s00705-015-2493-0.","journal-title":"Arch Virol"},{"key":"13878_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1590\/0037-8682-0024-2014","volume":"47","author":"M Mandour","year":"2014","unstructured":"Mandour M, Nemr N, Kishk R, Ahmed E. Impact of the IL-18 gene polymorphism in response to antiviral therapy in chronic HCV genotype 4 patients. Rev Soc Bras Med Trop. 2014;47:137\u201342. https:\/\/doi.org\/10.1590\/0037-8682-0024-2014.","journal-title":"Rev Soc Bras Med Trop"},{"key":"13878_CR17","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.12659\/MSM.914039","volume":"25","author":"J Ma","year":"2019","unstructured":"Ma J, Lv Z, Wang J, Lu J, Relationship Between. IL-10 Gene Polymorphism and Spinal Tuberculosis. Med Sci Monit. 2019;25:4901\u20136. https:\/\/doi.org\/10.12659\/MSM.914039.","journal-title":"Med Sci Monit"},{"key":"13878_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00439-024-02670-5","volume":"143","author":"C Riccio","year":"2024","unstructured":"Riccio C, Jansen ML, Guo L, Ziegler A. Variant effect predictors: a systematic review and practical guide. Hum Genet. 2024;143:625\u201334. https:\/\/doi.org\/10.1007\/s00439-024-02670-5.","journal-title":"Hum Genet"},{"key":"13878_CR19","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/humu.24298","volume":"43","author":"SE Hunt","year":"2022","unstructured":"Hunt SE, Moore B, Amode RM, Armean IM, Lemos D, Mushtaq A, et al. Annotating and prioritizing genomic variants using the Ensembl Variant Effect Predictor\u2014A tutorial. Hum Mutat. 2022;43:986\u201397. https:\/\/doi.org\/10.1002\/humu.24298.","journal-title":"Hum Mutat"},{"key":"13878_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17:122. https:\/\/doi.org\/10.1186\/s13059-016-0974-4.","journal-title":"Genome Biol"},{"key":"13878_CR21","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1136\/gutjnl-2024-332034","volume":"73","author":"H El-Serag","year":"2024","unstructured":"El-Serag H, Kanwal F, Ning J, Powell H, Khaderi S, Singal AG, et al. Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis. Gut. 2024;73:1000\u20137. https:\/\/doi.org\/10.1136\/gutjnl-2024-332034.","journal-title":"Gut"},{"key":"13878_CR22","doi-asserted-by":"publisher","unstructured":"Dhaouadi T, Riahi A, Ben Abdallah T, Gorgi Y, Sfar I. Impact of IL-10 gene promoter polymorphisms on treatment response in HCV patients: A systematic review, a meta-analysis, and a meta-regression. Int J Immunopathol Pharmacol. 2024;38. https:\/\/doi.org\/10.1177\/03946320241240705.","DOI":"10.1177\/03946320241240705"},{"key":"13878_CR23","doi-asserted-by":"publisher","first-page":"382","DOI":"10.2174\/1568009620666200319102929","volume":"20","author":"S EL-Sharawy","year":"2020","unstructured":"EL-Sharawy S, Negm OE-S, Abd-Elsalam S, EL-Sorogy HA, Shehata MAH. Study of Toll-like Receptor 3 Gene Polymorphism as a Novel Risk Factor for HCV-related Hepatocellular Carcinoma in Egypt. Curr Cancer Drug Targets. 2020;20:382\u20139. https:\/\/doi.org\/10.2174\/1568009620666200319102929.","journal-title":"Curr Cancer Drug Targets"},{"key":"13878_CR24","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1089\/vim.2022.0058","volume":"35","author":"RM Talaat","year":"2022","unstructured":"Talaat RM, Elsayed SS, Abdel-Hakem NE, El-Shenawy SZ. Genetic Polymorphism in Toll-Like Receptor 3 and Interferon Regulatory Factor 3 in Hepatitis C Virus-Infected Patients: Correlation with Liver Cirrhosis. Viral Immunol. 2022;35:609\u201315. https:\/\/doi.org\/10.1089\/vim.2022.0058.","journal-title":"Viral Immunol"},{"key":"13878_CR25","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1089\/jir.2020.0059","volume":"40","author":"RM Dawood","year":"2020","unstructured":"Dawood RM, El-Meguid MA, Salum GM, El Awady MK. Key Players of Hepatic Fibrosis. J Interferon Cytokine Res. 2020;40:472\u201389. https:\/\/doi.org\/10.1089\/jir.2020.0059.","journal-title":"J Interferon Cytokine Res"},{"key":"13878_CR26","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12902-021-00906-3","volume":"21","author":"M Zheng","year":"2021","unstructured":"Zheng M, Fang W, Yu M, Ding R, Zeng H, Huang Y, et al. IL-6 and IL-10 gene polymorphisms and cirrhosis of liver risk from a comprehensive analysis. BMC Endocr Disord. 2021;21:242. https:\/\/doi.org\/10.1186\/s12902-021-00906-3.","journal-title":"BMC Endocr Disord"},{"key":"13878_CR27","doi-asserted-by":"publisher","unstructured":"Cao LN, Cheng SL, Liu W. IL10 rs1800896 polymorphism is associated with liver cirrhosis and chronic hepatitis B. Genet Mol Res. 2016;15. https:\/\/doi.org\/10.4238\/gmr.15017256.","DOI":"10.4238\/gmr.15017256"},{"key":"13878_CR28","doi-asserted-by":"publisher","unstructured":"Du Y, Li S, Wang X, Liu J, Gao Y, Lv W, et al. Meta-analysis of the association between toll-like receptor gene polymorphisms and hepatitis C virus infection. Front Microbiol. 2023;14. https:\/\/doi.org\/10.3389\/fmicb.2023.1254805.","DOI":"10.3389\/fmicb.2023.1254805"},{"key":"13878_CR29","doi-asserted-by":"publisher","unstructured":"Mohan AL-SA, Khalaj-Kondori M, Mohammed Saud A. Interleukin 10 Cytokine Polymorphism (rs1800896) Association with the Hepatitis C in Patients from Iraq. Hepat Mon. 2025;25. https:\/\/doi.org\/10.5812\/hepatmon-158038.","DOI":"10.5812\/hepatmon-158038"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13878-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13878-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13878-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:07:08Z","timestamp":1784610428000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13878-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13878"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13878-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was done after approval from the Ethics Committee of the Faculty of Pharmacy- Ain Shams University, with approval number ACUC-FP-ASU RHIDIRB2020110301 REC #1. The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. Ethical approval was obtained from the Faculty of Pharmacy - Ain Shams University. Written informed consents were obtained from all participants according to f the National Committee for Control of Viral Hepatitis in Egypt and the Ethics Committee of the Faculty of Pharmacy- Ain Shams University (approval number ACUC-FP-ASU RHIDIRB2020110301 REC #1).","order":1,"name":"Ethics","label":"Human ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A written informed consent was obtained from all participants, according to the ethical guidelines of the National Committee for Control of Viral Hepatitis in Egypt and the Ethics Committee of the Faculty of Pharmacy- Ain Shams University, Egypt, with approval number ACUC-FP-ASU RHIDIRB2020110301 REC #1.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was done after obtaining written informed consent from the National Committee for Control of Viral Hepatitis in Egypt and from healthy control participants.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1379"}}